Genprex (NASDAQ:GNPX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.
GNPX has been the topic of a number of other research reports. Zacks Investment Research upgraded Genprex from a “sell” rating to a “hold” rating in a research note on Tuesday, June 18th. Noble Financial started coverage on Genprex in a research note on Monday, April 29th. They issued an “outperform” rating and a $5.00 price target on the stock.
Shares of GNPX traded up $0.08 during midday trading on Thursday, reaching $0.95. 8,547 shares of the company were exchanged, compared to its average volume of 68,937. The company’s 50-day moving average is $1.18. The stock has a market capitalization of $15.48 million, a P/E ratio of -1.06 and a beta of 1.49. Genprex has a 1-year low of $0.64 and a 1-year high of $3.30.
Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.09. As a group, sell-side analysts predict that Genprex will post -0.87 EPS for the current fiscal year.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Featured Article: Key terms to understand channel trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.